CLINICAL TRIAL SUMMARY

MDACC Study No:2011-0987 (clinicaltrials.gov NCT No: NCT01515527)
Title:PHASE II STUDY OF CLADRIBINE PLUS LOW DOSE CYTARABINE (LDAC) INDUCTION FOLLOWED BY CONSOLIDATION WITH CLADRIBINE PLUS LDAC ALTERNATING WITH DECITABINE IN PATIENTS WITH UNTREATED AML OR HIGH-RISK MDS
Principal Investigator:Tapan Kadia
Treatment Agent:Cladribine; Cytarabine; Decitabine
Study Status:Open
Study Description:The goal of this clinical research study is to learn if cladribine given in
combination with low-dose cytarabine (LDAC) and decitabine can help control the
disease in patients with AML or MDS. The safety of this drug combination will
also be studied.

Cladribine is designed to interfere with the cell's ability to process DNA (the
genetic material of cells). It can also insert itself into the DNA of cancer
cells to stop them from growing and repairing themselves.

Cytarabine is designed to insert itself into DNA of cancer cells to stop them
from growing and repairing themselves.

Decitabine is designed to damage the DNA of cells, which may cause cancer cells
to die.

Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:Cladribine
Cytarabine
Decitabine
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:N/A
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Tapan Kadia
Dept:Leukemia
For Clinical Trial Enrollment:713-563-3534
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults